文献速递炎症性肠病消化道肿瘤与早癌

系统综述与荟萃分析:5-氨基水杨酸使用与炎症性肠病患者结直肠肿瘤风险

Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-03-06

该系统综述与荟萃分析纳入31项观察性研究、2137例结直肠肿瘤(76%为癌),评估5-氨基水杨酸使用与炎症性肠病患者结直肠肿瘤风险的关联。总体分析显示5-氨基水杨酸使用与结直肠肿瘤风险降低相关(RR=0.57,95%CI:0.45-0.71),在溃疡性结肠炎中保护作用强(RR=0.50,95%CI:0.38-0.64),在克罗恩病中无统计学意义(RR=0.76,95%CI:0.43-1.33)。作者认为5-氨基水杨酸在炎症性肠病中具有潜在化学预防作用,需进一步高质量前瞻性研究。

要点

  • 5-氨基水杨酸使用与结直肠肿瘤风险降低相关(RR=0.57,95%CI:0.45-0.71)。
  • 溃疡性结肠炎中保护作用强(RR=0.50,95%CI:0.38-0.64),克罗恩病中无统计学意义(RR=0.76,95%CI:0.43-1.33)。
  • 美沙拉秦使用有保护作用(RR=0.70,95%CI:0.51-0.94)且存在剂量效应证据。

核心结论

  • 研究结果支持5-氨基水杨酸在炎症性肠病中具有潜在的化学预防作用,需进一步高质量前瞻性研究。

研究设计与样本

  • 对截至2016年12月检索PubMed、Scopus及主要会议论文集所获观察性研究进行更新的荟萃分析,采用随机效应模型计算合并相对危险度(RR),并进行详细亚组分析,采用GRADE方法评估证据质量。
  • 共纳入31项独立观察性研究,包括2137例结直肠肿瘤病例(其中76%为癌症)。

主要发现

  • 总体分析显示5-氨基水杨酸使用与结直肠肿瘤风险降低相关(RR=0.57,95%CI:0.45-0.71)。
  • 按研究设计分层:队列研究中关联显著(RR=0.65,95%CI:0.43-0.99;n=10),病例对照研究中关联显著(RR=0.53,95%CI:0.40-0.70;n=21)。
  • 按研究场景分层:人群为基础的研究中关联显著(RR=0.70,95%CI:0.52-0.94;n=12),医院为基础的研究中关联显著(RR=0.46,95%CI:0.34-0.61;n=19)。
  • 5-氨基水杨酸暴露对癌症有保护作用(RR=0.58,95%CI:0.45-0.74),对异型增生有保护作用(RR=0.54,95%CI:0.35-0.84)。
  • 溃疡性结肠炎中结直肠肿瘤风险降低作用强(RR=0.50,95%CI:0.38-0.64),克罗恩病中无统计学意义(RR=0.76,95%CI:0.43-1.33)。

关键数值与推荐

  • 总体5-氨基水杨酸使用与结直肠肿瘤风险的合并RR=0.57(95%CI:0.45-0.71)。
  • 队列研究RR=0.65(95%CI:0.43-0.99;n=10),病例对照研究RR=0.53(95%CI:0.40-0.70;n=21)。
  • 人群为基础研究RR=0.70(95%CI:0.52-0.94;n=12),医院为基础研究RR=0.46(95%CI:0.34-0.61;n=19)。
  • 癌症RR=0.58(95%CI:0.45-0.74),异型增生RR=0.54(95%CI:0.35-0.84)。
  • 溃疡性结肠炎RR=0.50(95%CI:0.38-0.64),克罗恩病RR=0.76(95%CI:0.43-1.33),美沙拉秦RR=0.70(95%CI:0.51-0.94),柳氮磺吡啶RR=0.72(95%CI:0.51-1.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究间异质性为中等,并高度怀疑存在小样本研究效应。
  • 作者结论指出需进一步高质量前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship of 5-aminosalicylates' use with the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD) has been the focus of a growing body of research. AIM: To investigate this association through an updated meta-analysis of observational studies. METHODS: PubMed, Scopus and major conference proceedings were searched up to December 2016. The identified studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates were calculated using random-effect models. Detailed subgroup analyses were performed. The GRADE approach was used to assess the quality of evidence. RESULTS: Thirty-one independent observational studies including 2137 cases of colorectal neoplasia (of which 76% were cancers) were incorporated. Between-study heterogeneity was moderate, while strong suspicion of small-study effects was raised. The overall analysis revealed a protective association between 5-aminosalicylates' use and colorectal neoplasia (RR = 0.57, 95% CI: 0.45-0.71). When the analysis was stratified according to study design and setting, the association was significant in cohort (RR = 0.65, 95% CI: 0.43-0.99; n = 10) and case-control studies (RR = 0.53, 95% CI: 0.40-0.70; n = 21), population-based (RR = 0.70, 95% CI: 0.52-0.94; n = 12) and hospital-based studies (RR = 0.46, 95% CI: 0.34-0.61; n = 19). Exposure to 5-aminosalicylates was protective against cancer (RR = 0.58, 95% CI: 0.45-0.74) and dysplasia (RR = 0.54, 95% CI: 0.35-0.84). The reduction in colorectal neoplasia risk was strong in ulcerative colitis (RR = 0.50, 95% CI: 0.38-0.64), but nonsignificant in Crohn's disease (RR = 0.76, 95% CI: 0.43-1.33). Mesalazine (mesalamine) use was protective (RR = 0.70, 95% CI: 0.51-0.94) with evidence of a dose-effect. The effect of sulfasalazine was marginally nonsignificant (RR = 0.72, 95% CI: 0.51-1.01). CONCLUSIONS: Our findings support a potential chemopreventive role of 5-aminosalicylates in IBD. Further, high-quality prospective research is warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28261835. doi:10.1111/apt.14023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。